Value and reasonable selection of surgery in advanced gastric cancer

Zi-yu LI,Kan XUE,Jia-fu JI
DOI: https://doi.org/10.19538/j.cjps.issn1005-2208.2017.10.02
2017-01-01
Abstract:Advanced gastric cancer has poor prognosis.Chemotherapy or with targeted drug is the primary treatment.Retrospective studies implied that surgery could relieve emergencies such as bleeding and obstruction,as well as improve survival for selected patients.In addition,the progress of drug therapy gave birth to the concept of conversion therapy,which further affirmed the value of surgery in advanced gastric cancer.However,it is still lack of evidence in the choice of surgical group,surgery opportunity,operation scope and postoperative treatment.Based on the advanced gastric cancer classification proposed by the authors' center,every patient should be discussed through MDT.For resectable tumor with less burden,the principle resembles neoadjuvant chemotherapy and the surgery aims at R0.For unresectable tumor with more burden,surgery is only conducted in patients after effective systemic therapy,and the ideal surgery should be performed after effective treatment and also before drug resistance.The operation scope should also consider the complication and slow postoperative recovery which possibly delay or interrupt systemic treatment.Postoperative systemic treatment should be considered.However,systemic treatment is still the cornerstone of advanced gastric cancer.Surgery should still be performed cautiously in highly selected patients before more solid evidence existed.The treatment effect depends on further exploration of effective drugs and genotyping markers.
What problem does this paper attempt to address?